The Manila Times23h
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...
MyChesCo on MSN23h
Endo, Inc. Shares Positive Data on XIAFLEX Treatment for Peyronie’s Disease
Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® ...
Research Analysts Issue Forecasts for ZVRA FY2025 Earnings
Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Zevra ...
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00
Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 ...